环氧化酶-2抑制剂预防重症急性胰腺炎的随机对照临床试验
本研究将190例预测为重症急性胰腺炎的患者随机分为常规治疗组和常规治疗联合环氧化酶-2抑制剂组,联合组依次给予帕瑞昔布和塞来昔布。结果显示联合组重症急性胰腺炎发生率较常规组降低47.08%(21.05% vs 39.78%,P=0.005),晚期局部并发症减少,血清IL-6和TNF-α水平显著降低。
要点
- 预测SAP患者联合COX-2抑制剂可降低SAP发生率约一半。
- 联合治疗还减少晚期局部并发症并快速缓解腹痛。
- 机制可能与降低血清IL-6和TNF-α水平有关。
核心结论
- 在预测为重症急性胰腺炎的患者中,序贯使用帕瑞昔布和塞来昔布可使SAP发生率降低约一半,并减少晚期局部并发症。
研究设计与样本
- 随机对照临床试验,共纳入190例预测为重症急性胰腺炎的患者,随机分为常规治疗组和常规治疗联合COX-2抑制剂组。
主要发现
- 联合组SAP发生率为21.05%(20/95),常规组为39.78%(37/93),P=0.005,联合组降低47.08%。
- 联合组晚期局部并发症发生率为18.95%(18/93),常规组为34.41%(32/95),P=0.016。
- 联合组血清IL-6和TNF-α水平显著低于常规组,P<0.05。
- 帕瑞昔布更快速缓解腹痛并减少哌替啶用量。
- SAP发生率每降低1%的增量成本为475元人民币。
关键数值与推荐
- 联合组用药方案:帕瑞昔布40 mg/d静脉注射3天,随后塞来昔布200 mg口服或管饲每日两次,共7天。
临床怎么用
- 对预测为重症急性胰腺炎的患者,在常规治疗基础上可考虑序贯使用帕瑞昔布和塞来昔布以预防SAP。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Severe acute pancreatitis (SAP) is still a big challenge. Accumulated data showed that overexpression of cyclooxygenase-2 (COX-2) in acute pancreatitis and experimental pancreatitis could be attenuated with COX-2 inhibitors. This study was aimed to evaluate whether the occurrence of SAP could be prevented by selective COX-2 inhibitors. METHODS: A total of 190 patients with predicted SAP were randomized into convention group or convention plus COX-2 inhibitors (C+COX-2-Is) group. Besides conventional treatment to all patients in 2 groups, parecoxib (40 mg/d intravenous injection for 3 days) and celecoxib (200 mg oral or tube feeding twice daily for 7 days) were sequentially administrated to the patients in the C+COX-2-Is group. The primary outcome was predefined as the occurrence of SAP. The serum levels of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) for all of the patients were measured. RESULTS: The occurrence of SAP in the C+COX-2-Is group was decreased 47.08% compared with the convention group, 21.05% (20/95) vs 39.78% (37/93), P = 0.005. A reduction of late local complications was also shown in the C+COX-2-Is group, 18.95% (18/93) vs 34.41% (32/95), P = 0.016. The serum levels of IL-6 and TNF-α were significantly lower in the C+COX-2-Is group than those in the convention group, P < 0.05. Parecoxib relieved abdominal pain more rapidly and decreased the consumption of meperidine. An incremental reduction of cost for 1% decrease of SAP occurrence was RMB475. DISCUSSION: Sequential administration of parecoxib and celecoxib in patients with predicted SAP obtained about half-reduction of SAP occurrence through decreasing serum levels of TNF-α and IL-6. This regimen presented good cost-effectiveness.
引用
- Huang Z, Ma X, Jia X, et al. Prevention of Severe Acute Pancreatitis With Cyclooxygenase-2 Inhibitors: A Randomized Controlled Clinical Trial. Am J Gastroenterol. 2020. PMID: 32142484. doi:10.14309/ajg.0000000000000529
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。